Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
88 hedge funds and large institutions have $378M invested in Marinus Pharmaceuticals, Inc in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 13 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 16
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
23% more capital invested
Capital invested by funds: $307M → $378M (+$70.4M)
14% more funds holding
Funds holding: 77 → 88 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
50% less call options, than puts
Call options by funds: $6.33M | Put options by funds: $12.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$19.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.1M |
| 3 |
LPC
Lion Point Capital
New York
|
+$12.5M |
| 4 |
6CM
683 Capital Management
New York
|
+$11.8M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$9.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IM
Islet Management
New York
|
-$8.35M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$7.33M |
| 3 |
JG
Jefferies Group
New York
|
-$6.53M |
| 4 |
Millennium Management
New York
|
-$4.33M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$1.49M |
MRNS Hedge Fund Activity: Q4 2020 in Review
88 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2020, worth a combined $378M — up 23% from $307M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MRNS positions and 13 closed out — a net gain of 11 holders — while 37 added to existing stakes and 16 trimmed.
The largest buyer was VR Adviser, adding an estimated $19.5M. The largest seller was Islet Management, exiting entirely with an estimated $8.35M sold.
- 88 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2020, up from 77 in Q3 2020.
- Funds reported $378M of Marinus Pharmaceuticals, Inc stock for Q4 2020, up 23% quarter-over-quarter.
- 24 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2020 and 13 closed out, a net change of +11 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2020 was VR Adviser, an estimated $19.5M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2020 was Islet Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q4 2020.